The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers.

导出 LinkOut

翻译打印收藏纠错

作者： Chiara M,Biatta ^[1] ; Michele,Paudice ^[1] ; Marco,Greppi ^[2] ; Veronica,Parrella ^[3] ; Alessia,Parodi ^[1] ; Giuseppa,De Luca ^[1] ; Gianna Maria,Cerruti ^[4] ; Serafina,Mammoliti ^[4] ; Cinzia,Caroti ^[5] ; Paola,Menichini ^[6] ; Gilberto,Fronza ^[7] ; Silvia,Pesce ^[7] ; Emanuela,Marcenaro ^[3] ; Valerio G,Vellone ^[3]

作者单位： Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, Genoa, Italy. ^[1] Pathology University Unit, IRCCS Ospedale Policlinico S. Martino, Genoa, Italy. ^[2] Department of Experimental Medicine (DIMES), University of Genova, Genoa, Italy. ^[3] Molecular Diagnostic Unit, IRCCS Ospedale Policlinico S. Martino, Genoa, Italy. ^[4] Oncology Unit, IRCCS San Martino IST, Genoa, Italy. ^[5] Oncology University Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. ^[6] Mutagenesis and Cancer Prevention Unit, IRCCS Ospedale Policlinico S.Martino, Genoa, Italy. ^[7] IRCCS Ospedale Policlinico San Martino, Genova, Italy. ^[8] Pathology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy. ^[9]

关键词 TP53 high grade serous ovarian carcinoma immunohistochemistry ovarian cancer sanger sequencing

主题词人类(Humans);女(雌)性(Female);肿瘤抑制蛋白质p53(Tumor Suppressor Protein p53);突变(Mutation);卵巢肿瘤(Ovarian Neoplasms)

DOI 10.3389/fimmu.2023.1221605

PMID 37680633

发布时间 2023-09-15

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交